Cardima surgical ablation probe receives EU approval
9 April 2009
Cardima, Inc. (OTCBB: CADM) has received CE Mark approval for its
Surgical Ablation Probe with Stabilization Sheath. The system can be
used in open-chest surgery in conjunction with other procedures, or as a
thoroscopic standalone, closed-chest procedure.
“Our discussions with European thought leaders cause us to believe
there is a tremendous opportunity in Europe for the Cardima Surgical
Ablation System for cardiac ablation procedures,” said Robert Cheney,
Chief Executive Officer of Cardima.
“Our System has patented technology that allows for creating deep,
long, linear and transmural cardiac lesions. The Cardima Surgical
Ablation System can be used in either closed- or open-chest procedures.
Additionally, our system treats both the left and right atria, which we
believe is necessary for the successful treatment of arrhythmias.
"We plan to market the Cardima Surgical Ablation System in Europe
through distribution partners, and will begin treating patients through
a network of cardiothoracic surgeon thought-leaders and developing
centres of excellence at key clinical sites in Europe.”
The Surgical Ablation Probe with Stabilization Sheath is a
microcatheter-based surgical probe powered by the company’s Intellitemp
radiofrequency (RF) energy management device. Together these components
comprise the Cardima Surgical Ablation System.
The Surgical Ablation Probe allows for creation of cardiac lesions
without gaps through the use of radiofrequency and Intellitemp’s
'controlled RF' technology. The Probe’s small, flexible design offers
sole port-hole access and incorporates irrigation, suction and
illumination, which aid in placement and lesion depth.
Bookmark this page